Study Overview: This study is testing treatments for advanced liver cancer called hepatocellular carcinoma (HCC). It compares two groups: one receiving a treatment mix called FOLFOX-HAIC with two drugs, lenvatinib and toripalimab, and another receiving FOLFOX-HAIC with just lenvatinib. FOLFOX-HAIC is a type of chemotherapy given directly into the liver, while lenvatinib and toripalimab are medications that help the immune system fight cancer. Eligibility: To join, patients need a specific liver cancer diagnosis and meet certain health criteria, like no prior treatment and good liver function. They should also understand the study and agree to participate. Important Points:

• Participants must have advanced liver cancer with measurable tumors.
• The study requires no previous liver cancer treatments.
• Participants with hepatitis B can join if they receive antiviral therapy.

This study helps understand if adding toripalimab to the treatment improves outcomes compared to lenvatinib alone.